Anthracyclines have been a cornerstone in the cure of diffuse large B-cell lymphoma (DLBCL) and other hematological cancers. The ability of anthracyclines to eliminate DLBCL depends on the presence of topoisomerase-II-alpha (TopIIA), a DNA repair enzyme complex. We identified nucleolin as a novel binding partner of TopIIA. Abrogation of nucleolin sensitized DLBCL cells to TopIIA targeting agents (doxorubicin/etoposide). Silencing nucleolin and challenging DLBCL cells with doxorubicin enhanced the phosphorylation of H2AX (γH2AX-marker of DNA damage) and allowed DNA fragmentation. Reconstitution of nucleolin expression in nucleolin-knockdown DLBCL cells prevented TopIIA targeting agent-induced apoptosis. Nucleolin binding to TopIIA was mapped to RNA-binding domain 3 of nucleolin, and this interaction was essential for blocking DNA damage and apoptosis. Nucleolin silencing decreased TopIIA decatenation activity, but enhanced formation of TopIIA-DNA cleavable complexes in the presence of etoposide. Moreover, combining nucleolin inhibitors: aptamer AS1411 or nucant N6L with doxorubicin reduced DLBCL cell survival. These findings are of clinical importance because low nucleolin levels versus high nucleolin levels in DLBCL predicted 90-month estimated survival of 70% versus 12% (P o 0.0001) of patients treated with R-CHOP-based therapy.
INTRODUCTION
Diffuse large B-cell lymphoma (DLBCL) is the most common histology of non-Hodgkin lymphoma and has a variable response to anthracycline-containing regimens. 1 Despite the recent improvement in therapy with the addition of immunotherapy to anthracycline-containing regimens, only 50% of DLBCL patients are cured. 2 In our search for improving DLBCL outcomes, we examined cell response to therapy.
Topoisomerase-II alpha (TopIIA) is a multifunctional nuclear enzyme required during DNA replication, transcription, chromosome segregation and DNA damage repair because of its ability to relax supercoiled DNA and decatenate/catenate double-stranded DNA rings. TopIIA also plays an important role in cell proliferation and chemotherapy resistance. 3, 4 TopIIA targeting agents doxorubicin and etoposide suppress the religation steps catalyzed by TopIIA, thus allowing accumulation of covalent TopIIA-DNA cleavage complexes. 4 In breast cancer, the appearance of TopIIA gene amplification predicts a better response to anthracyclinebased chemotherapy as well a longer overall survival in most studies. [5] [6] [7] DNA double-strand breaks (DSBs) arise through both endogenous (oxidative stress) and exogenous (ionization radiation or DNA damaging agents such as doxorubicin) insults inducing genomic instability. In response to the appearance of DSBs, cells undergo arrest of the cell cycle and initiate DNA repair, or if DNA damage is extensive, trigger apoptosis. In order to repair sites of DNA damage, both histone modification and chromatin remodeling are required to allow access for repair factors. Interestingly, nucleolin, which is normally a nucleolus-predominant protein, is drawn to DSBs induced by endonuclease or γ-radiation. 8, 9 Nucleolin is expressed ubiquitously, but elevated expression is primarily noted in cancers including DLBCL and proliferation-associated cells such as cancer-associated endothelial cells. [10] [11] [12] [13] [14] Nucleolin binds to several key DNA repair and recombination proteins such as topoisomerase-I, RAD50, MDC1, PCNA and γH2AX. 8, 9, 15, 16 To date, the functional importance of nucleolin in DNA damage response and interactions with repair proteins is not completely understood. In this current study, we identified nucleolin binding to TopIIA and this interaction is essential for regulating TopIIA targeting agents induced DLBCL cell death. Further, we demonstrate that low levels of nucleolin predict better survival of patients with DLBCL.
and isolated using CD19-positive magnetic beads as described previously and stored. 12 Patient DLBCL samples were collected with written consent of the patients at The University of Texas MD Anderson Cancer Center under research protocols LAB08-0190, 2008-0075 and 2005-0656 according to the Declaration of Helsinki. Primary DLBCL specimens having over 90% tumor cells to be included in the analysis after collection from effusions and lymphoma tumors. For protein expression, frozen stored DLBCL tissues and CD19 lymphocytes were thawed and processed side by side. Cells and tumor samples were lysed in cell lysis buffer (Cell Signaling Technologies, Danvers, MA, USA) supplemented with protease inhibitors (Roche, Basel, Switzerland) and calyculin A (Cell Signaling Technologies) on ice, and then combined with Laemmli sample buffer. Lysates were boiled and centrifuged in 4°C for 10 min at 10 000 g followed by western blotting.
Cell transfection and stable cell line generation
We knocked down nucleolin (NCL) in DLBCL cell lines by electroporation of specific nucleolin-targeting siRNA (AM16708; 144015 target exon 3; siR-1), control non-targeting (AM4635) (ThermoFisher, Waltham, MA, USA), SMARTpool-designed ON-TARGETplus siRNA (siR-2; J-003854-07, target exon 6) and siCONTROL non-targeting siRNA (siR-CON; D-001810) (Dharmacon/Thermo Scientific, Waltham, MA, USA) using the Neon Transfection System according to the manufacturer's instructions (Life Technologies, Carlsbad, CA, USA). Stable nucleolin knockdown cells were generated using lentiviruses expressing human nucleolin shRNA (sh-NCL-2; Sigma-Aldrich, St Louis, MO, USA; TRCN0000062283) targeting the UTR of nucleolin, cloned in pLKO.1 vector. 17 Transduced cells were selected with puromycin (1 μg/ml; Sigma-Aldrich). To reconstitute nucleolin expression in stable nucleolin-knockdown cells, plasmid (pCMV vector; Origene, Rockville, MD, USA) encoding C-terminal FLAG (DDK)-tagged full-length or deleted domain constructs of nucleolin were transfected into the cells using electroporation and selected with neomycin (G418, 1.0 mg/ml; PAA Laboratories, Little Chalfont, UK). Expression of exogenous nucleolin in the cells was confirmed with western blotting.
Comet assay DNA damage was measured using the comet assay. 18 Briefly, cells were mixed with pre-warmed 0.75% ultra-low gelling agarose (44415 2G; BDH Electran, BDH Laboratory Supplies, Safat, Kuwait) and layered on cold microscopic slides precoated with 0.1% agarose. After incubation at 4°C, lysis was carried out using lysis buffer (2.5% sodium dodecyl sulfate, 1% sodium sarcosinate, and 25 mM ethylene-diaminetetraacetic acid, pH 9.5) for 15 min at 25-30°C. Slides were washed for 5 min in distilled water at 10°C and electrophoresed (90 mM Tris base, 90 mM boric acid, 2.5 mM ethylene-diaminetetra-acetic acid, pH 8.3) at 2 V/cm for 5 min at 10°C. Cells were stained with propidium iodide and observed using a fluorescent microscope. Randomly one hundred cells were scored for comet length from three independent experiments. The length of the comet was measured across all cells using the ImageJ software (NIH, Bethesda, MD, USA); statistical T-test was used to determine the significance of the experiment.
Immunohistochemical analysis
Expression of nucleolin and TopIIA proteins was performed on 104 DLBCL patients who were uniformly treated with R-CHOP regimen. Immunohistochemistry (IHC) analysis was performed on tissue microarrays constructed with formalin-fixed, paraffin-embedded tissue using antibodies for Nucleolin (sc-55486; 1:6000) and TopIIA (12286; 1:600; Cell Signaling Technologies), as previously described. [19] [20] [21] High versus low and positive versus negative cutoffs were determined based on survival analysis using the X-tile software (version 3.6.1, Yale School of Medicine, New Haven, 
Statistical analysis
Clinico-pathologic features and biomarker correlation were analyzed using the Fisher exact test. Overall survival (OS) and progression-free survival (PFS) Kaplan-Meier analyses were performed using the GraphPad Prism-6 (GraphPad Software, San Diego, CA, USA). Data reported as means ± standard error of the mean for three independent experiments. Differences were compared between groups using the two-tailed Student' s t-test. All differences with P ⩽ 0.05 were considered statistically significant.
RESULTS

Nucleolin is overexpressed in DLBCL cells
Nucleolin protein expression was analyzed in DLBCL cell lines (SU-DHL-2,4,6,9 and HT), DLBCL tumors; BJAB cells (positive control); 12 and normal B cells from healthy donors by western blot analysis. DLBCL cell lines had higher levels of nucleolin expression over healthy donor B cells (Figure 1a ). In addition, primary DLBCL tissues samples had high, but variable nucleolin expression (Figure 1b) . To evaluate nucleolin expression in DLBCL, we performed IHC staining for nucleolin in 104 DLBCL patients. This patient population is representative of individuals presenting with DLBCL which were mostly elderly males with advanced stage DLBCL (Supplementary Table S1 ). Expression of nucleolin was found in 58 (55.7%) of 104 DLBCL cases. Figure 1c shows representative nucleolin staining. There was no significant difference of nucleolin expression between GCB and ABC subtypes (P = 0.058) (data not shown). The immunohistochemical cutoff for nucleolin overexpression associated with significant prognostic impact was determined by X-tile approach with maximum specificity and sensitivity. Using this method, the cutoff for nucleolin expression (nucleolin high ) was set at ⩾ 50%; 58 (55.7%) of 104 patients had nucleolin high DLBCL. These patients had significantly worse OS (P o 0.0001) and PFS (P o0.0001) than patients with nucleolin low DLBCL (Figure 1d) ). The 5-year OS rate was~35% for patients with nucleolin high DLBCL and~80% for patients with nucleolin low DLBCL. To further investigate the robustness of our results obtained for nucleolin protein expression by IHC, we analyzed the clinical outcomes using RNA expression data sets (two different cohorts of 119 patients (GSE4475) and 414 patients (GSE10846)) with DLBCL treated with CHOP-based therapy. 22, 23 Patients in each cohort were divided into two groups with high and low nucleolin mRNA levels. 24 The high nucleolin RNA-expressing groups in both patient cohorts had a significantly lower overall survival rate, as compared with the low nucleolin-expressing groups (Supplementary Figure S1b) . This is of fundamental interest as nucleolin is directly implicated in determining the fate of cells undergoing repair after induced DNA damage. 8 Nucleolin inhibits DLBCL cell death induced by TopIIA targeting agents Nucleolin has been previously shown to localize to DNA repair sites. Thus we first analyzed the levels of doxorubicin/etoposideinduced apoptosis after silencing nucleolin expression with two independent siRNAs (Figure 2a ). In all three DLBCL cell lines, the knockdown of nucleolin led to enhanced rates of TopIIA targeting agent-mediated cell apoptosis ( Figure 2b and Supplementary Figure S2a ). However, treatment with the TopIIA enzyme inhibitor dexrazoxane failed to induce cell death, suggesting that catalytic activity is not required for TopIIA targeting agent-mediated cell death (data not shown). Moreover, doxorubicin treatment generated higher levels of cleavage products of caspase 3, PARP and reduced BID expression in nucleolin-silenced cells, as compared with control ( Figure 2c ). Overall, nucleolin suppressed TopIIA targeting agent-mediated apoptosis in DLBCL.
Nucleolin suppresses TopIIA targeting agent-induced DNA damage in DLBCL cells Nucleolin exerts a plethora of functions, so to clarify its role in response to treatment with TopIIA targeting agents, 25 we examined DLBCL cells for DNA fragmentation as analyzed by the comet assay. Treatment with 0.1 μM doxorubicin or 1 μM etoposide caused comet-shaped distribution of DNA that was pronounced in nucleolin-knockdown cells (Figure 3a) . Phosphorylation of histone H2AX (γH2AX) at Ser-139 is an accepted marker for DSBs. 26 Treatment with doxorubicin or etoposide induced phosphorylation of H2AX in a dose-and time-dependent manner, while having no impact on the levels of TopIIA and H2AX (Figure 3b ). Silencing nucleolin followed by treatment with doxorubicin enhanced the phosphorylation of nuclear H2AX, again supporting the notion that the loss of nucleolin combined with a TopIIA targeting agent favors DNA damage (Supplementary Figure S2b) . In this study, the amount of drug used is sufficient to induce DNA damage leading to apoptosis or cell stress leading to DSB repair as reported previously. [27] [28] [29] Integrity of DNA depends on a balance between the rate of DNA damage and DNA repair. We evaluated the contribution of nucleolin to DNA repair by reducing basal nucleolin expression by 70%. Concomitant treatment with NU7026, a DNA-dependent protein kinase inhibitor and doxorubicin, 30 increased the γH2AX levels in nucleolin-silenced DLBCL cells as compared with control cells, implying that DNA repair was aided by the presence of NU7026 (Figure 3c) .
We further analyzed the effects of nucleolin in regulating TopIIA targeting agent-mediated DNA damage; we generated stable SU-DHL-9 and SU-DHL-4 nucleolin-knockdown cells by transducing them with a lentivirus expressing shRNA targeting the 3′UTR of nucleolin. We confirmed that shRNAs generated stable knockdowns, and were amenable to nucleolin reconstitution ( Figure 4a and Supplementary Figure S3a) . We transfected a full-length nucleolin (FLAG tagged) plasmid and selected with neomycin as described in 'Materials and methods' (Figure 4a (Figure 2 ). These acquired properties in sh-NCL-2 cells were reversed by exogenous nucleolin expression (sh-NCL-2+NCL cells) confirming that the effects were directly attributed to nucleolin (Figures 4d and e) . There was more caspase 3, PARP cleavage and reduced BID (22 kDa) expression in doxorubicin-treated sh-NCL-2 cells than in sh-CON or sh-NCL-2+NCL cells (Figure 4f ). Doxorubicin-induced phosphorylation of γH2AX was noticeably higher in sh-NCL-2 cells than in sh-CON or sh-NCL-2+NCL cells (Figures 4f and g ). Thus, independent analyses confirm that nucleolin suppresses TopIIA targeting agent-induced apoptosis in DLBCL cells.
Nucleolin-TopIIA interaction regulates TopIIA targeting agent's induced DNA damage Because nucleolin is associated with nucleic acid and prevents apoptosis, we hypothesized that nucleolin might directly interact with TopIIA to regulate cell death. We first screened for an interaction between nucleolin and TopIIA. Coimmunoprecipitation analysis with either nucleolin or TopIIA antibodies followed by western blotting in DLBCL cell lines (SU-DHL-4 and SU-DHL-9) confirmed the nucleolin-TopIIA association (Figure 5a) .
Having demonstrated the presence of TopIIA proteinnucleolin complexes, we embarked on mapping the domain of nucleolin required for binding to TopIIA by expressing nucleolin deletion mutants tagged with Myc-FLAG. 12 This analysis revealed that only the mutants harboring RBD3 domain of nucleolin or sh-NCL-2+NCL) treated with doxorubicin were stained for γH2AX/DAPI and analyzed using fluorescence microscopy. Bar = 20 μm. The fluorescence intensity of γH2AX signal of 100 cells were calculated using ImageJ software (NIH) and plotted. *P o0.05; **P o0.01; ***P o0.001. demonstrated the capacity to co-precipitate TopIIA (Figure 5b) . To delineate the functional implications of the nucleolin-TopIIA interaction, we analyzed the effects of nucleolin mutants on doxorubicin-induced apoptosis and DNA damage in DLBCL cells deficient in endogenous nucleolin. The empty FLAG vector (EV) or FLAG-tagged nucleolin constructs (full-length, NR123, NR12) were expressed in sh-NCL-2 cells. Western blot analysis using an anti-FLAG antibody confirmed the expression and levels of introduced nucleolin proteins (Figure 5c ). Expression of nucleolin full-length or NR123, but not NR12, in sh-NCL-2 cells rescued the impaired survival and apoptosis when treated with doxorubicin or etoposide (Figures 5d and e) . Moreover, phosphorylation of H2AX or cleavage/reduced of apoptosis markers (caspase 3, PARP, BID) after doxorubicin treatment was significantly increased in NR12-expressing cells but not in cells expressing nucleolin proteins capable of binding TopIIA (Figures 5f and g ). These results support the concept of TopIIA-nucleolin complexes being a prerequisite for preventing TopIIA targeting agentinduced DNA damage and apoptosis.
Nucleolin regulates TopIIA activity With these newly appointed properties of nucleolin on TopIIA, we characterized the effect of nucleolin on other TopIIA DNA repair functions. We measured the catalytic activity of TopIIA for decatenation of kinetoplast DNA (kDNA) with and without nucleolin. Catenated (interlinked) kDNA is the slow-moving band with minimal migration, as distinguished from decatenated (unlinked, monomer) kDNA (Supplementary Figure S4a,II,III) . We found less decatenated kDNA in extracts of nucleolin-silenced SU-DHL-9 cells than in control cells. Furthermore, we analyzed the effects of nucleolin on the DNA cleavage complexes formation. Treatment with etoposide induced cleavage of supercoiled pHOT-1 DNA and production of linear pHOT-1 in nuclear extracts (Supplementary Figure S4b) . We found less supercoiled pHOT and more linear pHOT DNA in nucleolin-silenced nuclear extracts in the presence of etoposide than in siR-CON cells, suggesting that nucleolin silencing enhances TopIIA targeting agent-mediated DNA cleavable complex formation.
To determine effects of nucleolin effect on TopIIA activity in DLBCL cells, we analyzed DNA-TopIIA complexes in cells exposed to etoposide. Cell extracts with chemically linked DNA-TopIIA were subjected to ultracentrifugation in a CsCl gradient and aliquots were blotted with anti-TopIIA antibody (Supplementary Figure S4c, Figure S4d) .
However, TopIIA is highly expressed in cancers and its expression was not significantly correlated with clinical outcomes in DLBCL. 33, 34 We performed IHC for TopIIA on the same 104 DLBCL patients reported in Figure 1 . We observed no significant impact of TopIIA expression on OS (P = 0.13) and PFS (P = 0.17) of DLBCL patients (Supplementary Figure S4e) . However, a significantly negative correlation of TopIIA expression with nucleolin levels was observed (Supplementary Figure S4f) . Further analysis revealed that the DLBCL patients with nucleolin low /TopIIA high had a significant (P o 0.0001) better outcome (OS, PFS) compared with other groups of DLBCL patients (Supplementary Figure 4g) . Our new data reported here indicate that TopIIA activity is modulated by nucleolin and the response of DLBCL cells to TopIIA targeting agents may depend on nucleolin-TopIIA complexes.
Because nucleolin expresses oncogenic properties and is selectively expressed on the cancer cell surface, it has been a promising target for cancer therapies. 35 We tested a nucleolinspecific aptamer (AS1411) on DLBCL cell survival. We compared uptake of FL-AS1411, a fluorescently labeled version of the active aptamer, with that of FL-CRO, a fluorescently labeled control oligonucleotide with no antiproliferative activity. FL-AS1411 uptake was more efficient by DLBCL cell lines (SU-DHL-4, SU-DHL-9) than control aptamer (Supplementary Figure S5a) . Moreover, AS1411 treatment inhibited the cell survival and proliferation of DLBCL cells without affecting nucleolin expression (Supplementary Figures S5b-d) . AS1411 treatment combined with doxorubicin/etoposide significantly inhibited cell survival of DLBCL cells (Figure 6a ). DLBCL cells treated with nucleolin antagonist (Nucant) N6L (synthetic peptides, that targets surface nucleolin with high affinity and selectivity) induced cell death with some activity at sub-micro-molar doses (Figure 6b and Supplementary Figure S6) . Thus, our results demonstrate that targeting nucleolin by several approaches improved the effects of chemotherapy.
DISCUSSION
TopIIA has a key role of sensing and repairing damaged DNA 3 and drugs that target TopIIA remain as critical components of therapy for lymphoma and leukemia. In this study, we found that TopIIA is regulated by nucleolin via nucleolin-TopIIA complex. This interaction promotes DNA repair and prevents apoptosis of DLBCL cells induced by TopIIA targeting agent (doxorubicin/etoposide) (Figure 6c ). Silencing of nucleolin expression permits accumulation of DNA damage and improves the killing effects of doxorubicin or etoposide (Figures 3 and 4) . Moreover, inhibition of nucleolin activity by application of nucleolin-specific aptamers (AS1411) or nucant (N6L) significantly decreased cell viability in the presence of doxorubicin ( Figure 6 and Supplementary Figures  S5 and S6 ). These findings are of clinical importance because low versus high nucleolin levels in DLBCL predicted 90-month estimated survival of 70% versus 12% (P o 0.0001) of patients treated with R-CHOP-based therapy (Figure 1d and Supplementary Figure S1) .
We found that depletion of nucleolin causes a robust accumulation of TopIIA-DNA complexes (Supplementary Figure S4c) and increased apoptosis of DLBCL cells after exposure to TopIIA targeting drugs (Figures 4e and f) . The presence of nucleolin cleared TopIIA-DNA complexes from the cells suggesting that nucleolin was preventing DNA damage or facilitating DNA damage repair to overall promote DNA integrity and prevent apoptosis. These nucleolin functions were confirmed by reconstitution of nucleolin in nucleolin-depleted cells. These nucleolin properties are not considered to occur secondary to nonspecific interactions of overexpressed protein, as the levels of introduced nucleolin and its derivative mutants were present at levels similar to those of endogenous nucleolin (Figures 4a and 5c ).
Numerous interacting partners have shown to regulate the DNA repair function of TopIIA. 3, 4, 31, 32, [36] [37] [38] [39] In the present study, we observed that nucleolin silencing enhanced TopIIA targeting agent-induced DNA damage, as evidenced by DNA fragmentation accumulation in comet assay (Figure 3a) and by phosphorylation of H2AX 26 and this effect was completely reversed by ectopic expression of nucleolin in nucleolin-silenced DLBCL cells (Figure 4g ). Nucleolin is composed of an N-terminal domain rich in acidic residues, a central domain containing 4 RNA-binding motifs (RBD), and a C-terminal domain rich in arginine and glycine residues (RGG or GAR domain). 40 RBD is known to bind the stemloop structure of RNA and mediates processing of ribosomal RNA. 40 We confirmed binding of nucleolin to TopIIA, and binding was restricted to RBD3 of nucleolin (Figures 5a and b) and binding is necessary for mediating effects on TopIIA functions. Our findings support the notion that nucleolin-TopIIA interaction regulates TopIIA targeting agent-mediated DNA damage and apoptosis of DLBCL cells, as the expression of a non-binding nucleolin deletion construct (NR12) failed to rescue TopIIAmediated DNA damage and apoptosis in nucleolin-knockdown cells (Figures 5c-g ). DSBs generated by TopIIA targeting agents' lead to immediate activation and recruitment of DNA repair components at DSB site. DNA damage response is mediated by protein sensors such as MRN (Mre11-Rad50-Nbs1) complexes, which trigger the activation of a signal transduction system including protein kinases ATM, ATR, Chk1 and p53. 41, 42 A previous report suggests that doxorubicin activates multiple ATM-dependent downstream targets required for DSBs repair. 28 Conversely, inhibition of ATM blocks the etoposide-induced DNA damage response and apoptosis in human T-cells, suggesting that ATM-regulated signaling is critical for DNA damage repair. 43 In another cell model, nucleolin recruited to DSBs via interaction with RAD50 through its GAR domain and facilitate DNA DSB repair by recruiting repair factors at DSB sites. 8 In our study, expression of RBD4-GAR deletion construct NR123 of nucleolin was able to rescue DNA damage/apoptosis defects in nucleolin-silenced DLBCL cells ( Figure 5 ). Thus, GAR is an optional domain for some DSB repairs. Our study is consistent to previous report where nucleolin-deficient cells exhibited increased γH2AX foci over control cells after γ-ray exposure. Accordingly, nucleolin appears as a participant in DNA repair regardless of source of damage. 9 In this current study, nucleolin modulating of TopIIA function is novel. We found that nucleolin silencing decreased TopIIA decatenation activity and enhanced formation of TopIIA-DNA cleavable complexes in DLBCL cells in the presence of etoposide (Supplementary Figures S4a-c) without affecting the TopIIA levels. This suggests that nucleolin as an interacting partner of TopIIA might be able to regulate its enzymatic activity by resolving DSB. This postulated regulation is consistent with previous reports indicating TopIIA interacting partners profoundly affect TopIIA enzyme activity. 3 For example, ATM and casein kinase I (CKI) enhance etoposide-stabilized TopIIA-DNA cleavable complex formation, 31, 32 and casein Kinase II (CKII) enhances decatenation activity of TopIIA. 36, 37 TopIIA itself serves as a substrate of many kinases, which phosphorylate and influence its enzymatic activity. 31, 32 In this study, we found that nucleolin silencing enhanced the phosphorylation of TopIIA at serine residue 1469, which is one of the mechanisms to alter TopIIA activity and enhance TopIIA-DNA cleavable complex formation ( Supplementary Figures S4c and d) . We speculate that nucleolin silencing might reduce the competition for binding to TopIIA, rendering TopIIA available to other kinases and their regulation.
High levels of TopIIA are associated in DLBCL patients who have improved clinical response to anthracycline-based chemotherapy. 33, 34 This clinical benefit stands in agreement with DNA repair capabilities provided by TopIIA. We observed no significant impact of TopIIA expression on OS and PFS of DLBCL patients (Supplementary Figure S4e) . Nucleolin is an important target that exerts prosurvival effect expected to transcend those mediated in partnership with TopIIA. Nucleolin dictates the expression of many genes such as Bcl-xL, AKT and IL-2 that regulate apoptosis and support the transformed cell phenotype. 14, 44, 45 In chronic lymphocytic leukemia, a 26-fold elevated level of nucleolin supports a 11-fold bcl-2 protein level by protecting bcl-2 mRNA.
14 Thus, nucleolin levels may serve as a predictive biomarker of anthracycline/etoposide sensitivity and a marker for survival with other apoptosis stimuli.
Nucleolin is highly expressed on surface of several types of cancer, rendering it an attractive target for cancer therapies. 12, 13, 35, 46 Earlier we demonstrated that primary nonHodgkin lymphoma including DLBCL expressed nucleolin on the cell surface whereas normal B cells lacked expression. 12 Nucleolin on cancer cell surfaces has gained recognition for having diverse functions such as shuttling and chaperone function for ligands, cytokines, acting as a receptor for viruses and regulating receptor functions. [10] [11] [12] [13] [14] [47] [48] [49] [50] [51] We have shown that silencing of nucleolin expression preferentially depletes the cell surface nucleolin and speculate that lack of surface nucleolin is sufficient to alter transmembrane signaling. 12 A number of molecules such as aptamers (AS1411) or peptides/immuno-agents (HB19, N6L, F3, 4LB5) have been known to inhibit nucleolin function and rely on access to cell surface nucleolin. [52] [53] [54] AS1411 is the first DNA aptamer that has reach phase I and II clinical trials for potential treatment of cancer including acute myelogenous leukemia. 55 Moreover, AS1411 kill acute myelogenous leukemia cells from patients at 5μM, without affecting normal B cell.
56,57 AS1411 conjugated to cytotoxic agents showed selective delivery of these agents to tumor cells. For example, gemcitabine (GEM)-loaded AS1411 aptamer surface-decorated nanopolymersome has been used in non-small cell lung cancer. 58 In mice xenografts, AS1411-doxorubicin conjugation has shown a specific uptake/release of drug in hepatocellular carcinoma and reduced tumor formation. 59 We found combined nucleolin-specific AS1411 and doxorubicin or etoposide treatment significantly inhibited the survival and proliferation of DLBCL cells (Figure 6a and Supplementary Figure S5 ). Similar results were obtained when DLBCL cells were treated with nucleolin-specific nucant N6L (Figure 6b and Supplementary Figure S6) . N6L treatment has strongly inhibited breast cancer growth by inducing apoptosis 60 and is currently aimed for phase II clinical trials (IPP-204106).
In conclusion, nucleolin binds to TopIIA and this interaction blocks the effects of TopIIA targeting agent-induced DNA damage and apoptosis of DLBCL. The efficacy of TopIIA targeting agents currently in clinical use might be enhanced by blocking nucleolin in DLBCL cells. We anticipate that targeting nucleolin by several approaches would improve the effects of chemotherapy for DLBCL.
